AR039697A1 - Analogos de adenosina y su uso como agentes farmaceuticos - Google Patents
Analogos de adenosina y su uso como agentes farmaceuticosInfo
- Publication number
- AR039697A1 AR039697A1 ARP030102151A ARP030102151A AR039697A1 AR 039697 A1 AR039697 A1 AR 039697A1 AR P030102151 A ARP030102151 A AR P030102151A AR P030102151 A ARP030102151 A AR P030102151A AR 039697 A1 AR039697 A1 AR 039697A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkylene
- group
- aryl
- hydrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Estos compuestos son útiles para la fabricación de un medicamento para el tratamiento de la resistencia a la insulina, la diabetes de tipo 2, el síndrome, metabólico, los trastornos lipídicos o la enfermedad cardiovascular, o para proporcionar un efecto antilipolítico. Reivindicación 1: Un compuesto según la fórmula general (1) en la que: W es N, N®O ó CH; Q es CH2 u O; R1 se selecciona del grupo que consiste en hidrógeno, alquilo C1-10, alilo, 2-metilalilo, 2-butenilo y cicloalquilo C1-10; X se selecciona del grupo de fórmulas (2), en los que n y p son independientemente 0, 1, 2 ó 3, con la condición de que n + p es al menos 1; y alquilen (C1-10)-Y, alquenilen (C1-10)-Y, ciclo-alquilen (C3-10)-Y y cicloalquenilen (C3-10)-Y no sustituido y al menos monosustituido, cuyos sustituyentes se seleccionan del grupo que consiste en halógenos, pseudohalógenos, CF3, alquilo C1-6 y alcoxi C1-6; E es O o S; Y se seleccionan del grupo que cosiste en hidrógeno; y alquilo C1-10, arilo, heterociclilo, aril-(alquileno C1-10)- y heterociclil-(alquileno C1-10) no sustituido y al menos no sustituido, cuyos sustituyentes se seleccionan del grupo que consiste en halógenos, pseudohalógenos, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heterociclilo, alcoxi C1-6, NH2, (alquil C1-6)amino, di(alquil C1-6)amino, alcoxi(C1-6)-(alquilenoC1-6)-, nitro, carboxi, carbalcoxi, carboxi-(alquileno C1-6)-, carbalcoxi-(alquileno C1-6)-, hidroxi, hidroxi-(alquileno C1-6)-, mercapto, (alquil C1-6)tio, mercapto-(alquileno C1-6)-, alquilo C1-6 no sustituido con al menos un halógeno, (alquil C1-6)sulfonilo-, aminosulfonilo-, (alquil C1-6)aminosulfonilo-, (alquil c1-6)sulfonilamido-, (alquil C1-6)-sulfonil-(alquilen C1-6)amino, HO3S-(alquilen C1-6)-carbamoil-(alquilen C1-6)-(alquil C1-6)-carbamoílo, (alquil C1-6)-C(O)O-, (alquil C1-6)-CO-, -SO3H y carbamoílo; T es un resto selecciona del grupo que consiste en alquilo C1-10, cicloalquilo C1-10, aril-(alquileno C1-10)- y heterociclil-(alquileno C1-10), estando dicho resto monosustituido con halógeno u OR2, y dicho resto puede estar opcionalmente sustituido con al menos otro sustituyente seleccionado del grupo que consiste en halógenos, pseudohalógenos, mercapto, NH2, nitro, hidroxi, alquilo C1-6, alcoxi C1-6, (alquil C1-6)amino, (alquil c1-6)tio, arilo y heterociclilo no sustituido y al menos monosustituido, cuyos sustituyentes se seleccionan del grupo que consiste en halógenos, pseudohalógenos, alquilo C1-3, alcoxi C1-3 e hidroxi; R2 es alquilo C1-10 sustituido con al menos un halógeno; A es hidrógeno, alquilo C1-10, hidroxi-(alquileno C1-10)-, alcoxi(C1-10)-(alquilenoC1-10)- u OR'; B es hidrógeno, alquilo C1-10, hidroxi-(alquileno C1-10)-, alcoxi(C1-10)-(alquilenoC1-10)- u OR''; R' y R'' se seleccionan independientemente del grupo que consiste en hidrógeno, alquilo C1-6, aril-(alquileno C1-6)-, (alquil C1-6)-CO, carbalcoxi, aril-(alquilen C1-6)-CO- y aril-O-CO-; en el A y B son OR' y OR'', respectivamente, y R' y R'' juntos pueden formar un sustituyente seleccionado del grupo de fórmula (3); Rc es hidrógeno o alquilo C1-6; Rd y Re son independientemente hidrógeno, alquilo C1-10, o junto con el átomo de carbono al cual están unidos pueden formar un grupo 1,1-cicloalquilo; heterociclilo es un heterociclo mono- o bicíclico de 4 a 10 miembros que contiene uno o más heteroátomos seleccionados del grupo que consiste en N, O y S; arilo es fenilo, indan-1-ilo, indan-2-ilo, naft-1-ilo o naft-2-ilo; o su sal farmacéuticamente aceptable, su profármaco farmacéuticamente aceptable, su N-óxido, su hidrato o su solvato; con la condición de que, en el caso en que Q es O e Y es hidrógeno, X no es cicloalquileno C3-6 o cicloalquileno C3-6 sustituido con al menos un halógeno; en el caso en que Q es O e Y es hidrógeno, alquilo C1-10 o alquilo C1-10 sustituido con al menos un hidroxi, X no es alquileno C1-10 no sustituido; en el caso en que Q es O e Y-X es 2-piridin-4-iletilo, T no es CF3OCH2-; en el caso en que Q es O y T es metilo monosustituido con halógeno, Y-X no es alquilo C1-10, alquenilo C1-10, 2-feniletilo o (cicloalquil C3-10)metilo no sustituido y sustituido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02014324A EP1375508A1 (en) | 2002-06-27 | 2002-06-27 | N6-substituted adenosine analogues and their use as pharmaceutical agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039697A1 true AR039697A1 (es) | 2005-03-09 |
Family
ID=29716849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030102151A AR039697A1 (es) | 2002-06-27 | 2003-06-18 | Analogos de adenosina y su uso como agentes farmaceuticos |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP1375508A1 (es) |
| JP (1) | JP2006501178A (es) |
| KR (1) | KR20050014888A (es) |
| CN (1) | CN1671728A (es) |
| AR (1) | AR039697A1 (es) |
| AU (1) | AU2003280141A1 (es) |
| BR (1) | BR0312428A (es) |
| CA (1) | CA2490253A1 (es) |
| HR (1) | HRP20041209A2 (es) |
| IL (1) | IL165934A0 (es) |
| MA (1) | MA27465A1 (es) |
| MX (1) | MXPA04012815A (es) |
| NO (1) | NO20050398L (es) |
| PE (1) | PE20040584A1 (es) |
| PL (1) | PL375197A1 (es) |
| RU (1) | RU2005101872A (es) |
| TW (1) | TW200500376A (es) |
| WO (1) | WO2004003002A1 (es) |
| ZA (1) | ZA200410062B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS51680B (sr) | 2005-09-21 | 2011-10-31 | Pfizer Limited | Derivati karboksamida kao antagonisti receptora muskarina |
| JP2007153789A (ja) * | 2005-12-05 | 2007-06-21 | Mitsui Chemicals Inc | 光学活性３−アミノピロリジン誘導体の製造方法 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN119039201A (zh) * | 2024-07-19 | 2024-11-29 | 苏州汉德创宏生化科技有限公司 | 一种(s)-1-叔丁氧羰基-3-氨基吡咯烷的合成方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1545645A1 (de) * | 1965-12-06 | 1969-08-21 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von disubstituierten Adenosin-Derivaten |
| AU575438B2 (en) * | 1984-10-26 | 1988-07-28 | Warner-Lambert Company | N6 - substituted deoxyribose analogues of adenosines |
| US4755594A (en) * | 1986-01-31 | 1988-07-05 | Warner-Lambert Company | N6 -substituted adenosines |
| AU8276187A (en) * | 1986-10-31 | 1988-05-25 | Warner-Lambert Company | Selected n6-substituted adenosines having selective a2 binding activity |
| WO1997033591A1 (en) * | 1996-03-13 | 1997-09-18 | Novo Nordisk A/S | A method of treating disorders related to cytokines in mammals |
| UA51716C2 (uk) * | 1996-07-08 | 2002-12-16 | Авентіс Фармасьютікалз Продактс Інк. | Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування |
| US6376472B1 (en) * | 1996-07-08 | 2002-04-23 | Aventis Pharmaceuticals, Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| EP0983768A1 (en) * | 1997-05-23 | 2000-03-08 | Nippon Shinyaku Co., Ltd. | Medicinal composition for prevention or treatment of hepatopathy |
| GB9723566D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| GB9723589D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
-
2002
- 2002-06-27 EP EP02014324A patent/EP1375508A1/en not_active Withdrawn
-
2003
- 2003-06-18 AR ARP030102151A patent/AR039697A1/es unknown
- 2003-06-25 PE PE2003000640A patent/PE20040584A1/es not_active Application Discontinuation
- 2003-06-26 HR HR20041209A patent/HRP20041209A2/hr not_active Application Discontinuation
- 2003-06-26 AU AU2003280141A patent/AU2003280141A1/en not_active Abandoned
- 2003-06-26 RU RU2005101872/04A patent/RU2005101872A/ru not_active Application Discontinuation
- 2003-06-26 KR KR10-2004-7021262A patent/KR20050014888A/ko not_active Withdrawn
- 2003-06-26 EP EP03740352A patent/EP1527083A1/en not_active Withdrawn
- 2003-06-26 MX MXPA04012815A patent/MXPA04012815A/es not_active Application Discontinuation
- 2003-06-26 CN CNA038179660A patent/CN1671728A/zh active Pending
- 2003-06-26 BR BR0312428-2A patent/BR0312428A/pt not_active IP Right Cessation
- 2003-06-26 TW TW092117351A patent/TW200500376A/zh unknown
- 2003-06-26 JP JP2004516688A patent/JP2006501178A/ja active Pending
- 2003-06-26 WO PCT/EP2003/006749 patent/WO2004003002A1/en not_active Ceased
- 2003-06-26 PL PL03375197A patent/PL375197A1/xx not_active Application Discontinuation
- 2003-06-26 IL IL16593403A patent/IL165934A0/xx unknown
- 2003-06-26 CA CA002490253A patent/CA2490253A1/en not_active Abandoned
-
2004
- 2004-12-13 ZA ZA200410062A patent/ZA200410062B/xx unknown
- 2004-12-24 MA MA28022A patent/MA27465A1/fr unknown
-
2005
- 2005-01-25 NO NO20050398A patent/NO20050398L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050014888A (ko) | 2005-02-07 |
| PE20040584A1 (es) | 2004-11-03 |
| HRP20041209A2 (en) | 2005-08-31 |
| IL165934A0 (en) | 2006-01-15 |
| RU2005101872A (ru) | 2005-08-10 |
| TW200500376A (en) | 2005-01-01 |
| EP1527083A1 (en) | 2005-05-04 |
| EP1375508A1 (en) | 2004-01-02 |
| CA2490253A1 (en) | 2004-01-08 |
| CN1671728A (zh) | 2005-09-21 |
| AU2003280141A1 (en) | 2004-01-19 |
| BR0312428A (pt) | 2005-04-26 |
| NO20050398L (no) | 2005-01-25 |
| PL375197A1 (en) | 2005-11-28 |
| WO2004003002A1 (en) | 2004-01-08 |
| JP2006501178A (ja) | 2006-01-12 |
| ZA200410062B (en) | 2008-08-27 |
| MA27465A1 (fr) | 2005-08-01 |
| MXPA04012815A (es) | 2005-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2495873C2 (ru) | Новое урациловое соединение или его соль, обладающие ингибирующей активностью относительно дезоксиуридинтрифосфатазы человека | |
| PE20230159A1 (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos | |
| ATE537830T1 (de) | Nicotinamid derivate und ihre verwendung als therapeutika | |
| AR069801A1 (es) | Derivados de aminotriazol | |
| CY1113450T1 (el) | Διαμινοπυριμιδινες ως ρ2χ3 και ρ2χ2/3 ανταγωνιστες | |
| AR057244A1 (es) | Compuestos agonistas,antagonistas o agonistas inversos de receptores cb2,composiciones farmaceuticas que los contienen, metodos de preparacion y usos para tratar enfermedades inflamatorias y/o autoinmunes. | |
| DK2298768T3 (da) | 5-Amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidinderivater og beslægtede forbindelser til behandling af cancer | |
| AR087301A1 (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide | |
| AR082519A1 (es) | Fenilamidinas que tienen alta actividad fungicida, y su utilizacion | |
| RU2005105337A (ru) | Противомикробные хинолины, их композиции и применение | |
| AR073932A1 (es) | Compuestos de esteres de acido 2-(aminometiliden)-4,4-difluoro-3- oxobutirico y procedimiento para su preparacion | |
| PE20080370A1 (es) | Derivados de quinazolinona como antagonistas de cgrp | |
| AR039697A1 (es) | Analogos de adenosina y su uso como agentes farmaceuticos | |
| AR046977A1 (es) | Dioxidos de isotiazol como ligandos del receptor cxc y cc-quimioquina | |
| RU2012110380A (ru) | Новое производное 5-фторурацила | |
| RU2013148146A (ru) | Производные адамантила | |
| NO20076425L (no) | Fremgangsmater for behandling av drug-resistent cancer | |
| FR2928151B1 (fr) | Derives platine-carbene n-heterocyclique, leur preparation et leur application en therapeutique | |
| EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
| MA33352B1 (fr) | Derives de cyclopenta[c]pyrrolylalkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique | |
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| AR067061A1 (es) | Utilizacion de un antagonista par1 en el tratamiento de la fibrilacion atrial | |
| DK1541197T3 (da) | Anvendelse af pipamperon og en SNDRI, SNRI eller SSRI til behandling af humörsvingninger eller angstlidelser | |
| AR109949A1 (es) | Derivados de fenilamina sustituidos en la posición 4 y uso de los mismos para proteger los cultivos combatiendo los microorganismos fitopatógenos no deseados | |
| HN2005000239A (es) | Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |